Welcome to our dedicated page for Sellas Life Sciences Group SEC filings (Ticker: SLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SELLAS Life Sciences Group, Inc. filings document a Nasdaq-listed clinical biopharmaceutical company developing cancer therapeutics, including GPS and SLS009 programs in acute myeloid leukemia. Form 8-K reports cover operating results, financial condition, corporate updates, clinical program disclosures, and material agreements.
The filing record also includes capital-structure disclosures for common stock and warrants, warrant inducement agreements and exercise proceeds, share-count updates, and facility-related agreements. Proxy materials document annual meeting proposals, stockholder voting procedures, and governance matters.
SELLAS Life Sciences Group, Inc. provides an update on its cash position and share count. The company had $107.1 million in cash and cash equivalents as of March 31, 2026. In April and May 2026, it received about $28.7 million from the exercise of common stock warrants, adding to its liquidity.
As of June 2, 2026, SELLAS had 196,632,574 shares of common stock outstanding, giving investors a clearer picture of the current capital structure.
SELLAS Life Sciences Group, Inc. reported a first quarter 2026 net loss of $8.4 million, or $0.05 per share, wider than the $5.8 million loss, or $0.07 per share, a year earlier. Higher research and development expenses of $5.1 million and general and administrative expenses of $4.1 million drove the increase as the company invested in clinical programs and regulatory preparation.
Cash and cash equivalents rose to $107.1 million as of March 31, 2026, with an additional $7.5 million received in the second quarter from warrant exercises. SELLAS highlighted progress in its pivotal Phase 3 REGAL trial of GPS in acute myeloid leukemia, with 78 of 80 required events reached as of May 11, 2026, and ongoing dosing in a Phase 2 trial of SLS009 in newly diagnosed AML. The company also put in place an at-the-market equity offering program allowing up to $150 million in future capital raises.
SELLAS Life Sciences Group, Inc. reported a net loss of $8.4 million for the quarter ended March 31, 2026, as it continues late-stage oncology drug development. Operating expenses rose to $9.3 million, driven by higher GPS manufacturing and regulatory work and increased legal and public company costs.
Cash and cash equivalents increased to $107.1 million, boosted by $44.1 million from the exercise of 28.2 million warrants during the quarter, plus a further $7.5 million from warrant exercises after March 31. Management believes this liquidity will fund planned operations for at least twelve months and has also put a $150 million at-the-market equity program in place.
The company is advancing two key programs: the Phase 3 REGAL trial of GPS in acute myeloid leukemia, approaching its final overall-survival analysis, and a randomized Phase 2 trial of SLS009 in newly diagnosed AML following positive Phase 2a results in relapsed/refractory AML. SELLAS also highlights multiple FDA orphan and rare pediatric disease designations and an ongoing arbitration with 3D Medicines over GPS milestones.
SELLAS LIFE SCIENCES GROUP INC ownership update: BlackRock, Inc. reports beneficial ownership of 12,136,331 shares, representing 6.8% of common stock. The filing attributes sole voting power for 11,966,938 shares and sole dispositive power for 12,136,331 shares, reported by a Managing Director.
SELLAS Life Sciences Group, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 16, 2026 at 8:30 a.m. Eastern Time. The meeting will be held online only via live webcast at www.virtualshareholdermeeting.com/SLS2026.
Stockholders will vote on five proposals, including electing two Class I directors to terms ending in 2029, ratifying Baker Tilly US, LLP as independent registered public accounting firm for 2026, and approving an amendment to the 2023 Equity Plan to increase shares authorized for issuance by 20,000,000. They will also cast a non-binding advisory vote on executive compensation and consider approval of any adjournment or postponement of the meeting if needed to secure enough proxies or establish a quorum.
Holders of SELLAS common stock at the close of business on April 21, 2026, when 184,532,574 shares were outstanding, are entitled to one vote per share. The board recommends voting “FOR” all five proposals and outlines detailed governance practices, committee structures, ownership guidelines, and 2025 executive pay, including total 2025 compensation of $1,877,810 for the Chief Executive Officer.
The Vanguard Group filed Amendment No. 1 to a Schedule 13G/A reporting zero beneficial ownership of SELLAS Life Sciences Group Inc common stock. The filing explains an internal realignment on January 12, 2026 that disaggregated certain Vanguard subsidiaries. The holdings disclosed are in the form of warrants. The filing is signed by Ashley Grim as Head of Global Fund Administration on 03/27/2026.
SELLAS Life Sciences Group, Inc. filed and amended a Form S-3 shelf registration to permit the offering, issuance and sale from time to time of an indeterminate amount of common stock, preferred stock, debt securities, warrants and/or units. The registration includes a sales agreement prospectus supplement allowing sales of common stock of up to $150,000,000 under an at-the-market arrangement with TD Securities (USA) LLC (TD Cowen). The base prospectus emphasizes that offerings will occur "from time to time after the effective date" and that specific terms will be set in prospectus supplements. The filing discloses cash and cash equivalents of $71.8 million as of December 31, 2025 and notes subsequent receipt of approximately $42.6 million from the exercise of common stock warrants.
SELLAS Life Sciences Group, Inc. reported a narrower 2025 net loss and a much stronger cash position while advancing its late-stage oncology pipeline. Net loss for 2025 was $26.9 million, or $0.25 per share, compared with $30.9 million, or $0.50 per share, in 2024. Research and development expenses fell to $16.0 million from $19.1 million, mainly after completing enrollment in the Phase 3 REGAL trial of GPS in acute myeloid leukemia. As of December 31, 2025, cash and cash equivalents were $71.8 million, boosted by $67.2 million of 2025 warrant exercise proceeds, with an additional $42.6 million raised from warrant exercises in Q1 2026.
The company is approaching final analysis of the event-driven Phase 3 REGAL study after recording 72 of the required 80 overall-survival events and highlighted positive Phase 2 SLS009 data in relapsed/refractory AML, where overall response was 46% among 35 evaluable patients and median overall survival reached 8.9 months in the least pretreated cohort. SELLAS has begun an 80-patient trial of SLS009 in newly diagnosed AML and entered a European collaboration with IMPACT-AML to study SLS009 with AZA/VEN in about 40 newly diagnosed patients starting in Q2 2026.
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company developing novel cancer therapies, led by its WT1-targeting immunotherapy galinpepimut‑S (GPS) and CDK9 inhibitor SLS009 (tambiciclib). The company remains development‑stage, with no product revenue and a history of substantial losses, and expects increasing losses as it advances its pipeline.
GPS is in a registrational Phase 3 REGAL trial as maintenance therapy for acute myeloid leukemia (AML) patients in second complete remission who are not candidates for stem‑cell transplant, with interim analysis completed and the final overall survival readout event‑driven. GPS has shown encouraging earlier‑stage signals in AML, mesothelioma and multiple myeloma and holds multiple FDA and EMA orphan and fast track designations, including Rare Pediatric Disease status in pediatric AML.
SLS009 has shown promising Phase 1 and Phase 2a results in relapsed/refractory AML and lymphomas, including activity in venetoclax‑resistant disease and defined recommended Phase 2 doses. A randomized Phase 2 trial in newly diagnosed AML patients eligible for azacitidine/venetoclax is enrolling, and European access is being expanded via the IMPACT‑AML network. The business depends heavily on successful clinical outcomes, additional financing, third‑party manufacturing and trials, and protection and execution of key licenses with MSK, GenFleet and 3D Medicines.